Get the Stockscreener App
2.2996
2.97%
-0.0604
Fate Therapeutics Inc stock is traded at $2.2996, with a volume of 1.62M.
It is down -2.97% in the last 24 hours and up +92.44% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$2.36
Open:
$2.4
24h Volume:
1.62M
Relative Volume:
0.92
Market Cap:
$266.40M
Revenue:
$6.65M
Net Income/Loss:
$-136.32M
P/E Ratio:
-2.0037
EPS:
-1.1477
Net Cash Flow:
$-112.04M
1W Performance:
+84.68%
1M Performance:
+92.44%
6M Performance:
+120.19%
1Y Performance:
+139.09%
1-Day Range:
$2.23
$2.41
1-Week Range:
$1.22
$2.41
52-Week Range:
$0.91
$2.41
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.291 | 274.42M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
429.46 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.42 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.49 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.42 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.03 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-27-25 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
HC Wainwright Issues Positive Estimate for FATE Earnings - MarketBeat
Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com - Investing.com South Africa
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program - Investing.com
Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819 - marketscreener.com
FDA picks Fate's lupus cell therapy for manufacturing-readiness pilot - Stock Titan
Fate Therapeutics Selected For U.S. FDA Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program To Support Manufacturing Readiness Of Ft819 - TradingView
Fate Therapeutics Selected for U.S. FDA Chemistry, - GlobeNewswire
Off-the-shelf CAR-T studies target lupus, diabetes and cancer - Stock Titan
Fate Therapeutics announces three presentations at the 2026 ASGCT annual meeting highlighting off-the-shelf CAR T-cell therapy pipeline for cancer and autoimmune diseases - marketscreener.com
Fate Therapeutics Announces Three Presentations at the 2026 - GlobeNewswire
H.C. Wainwright raises Fate Therapeutics price target to $7 on SLE data - Investing.com Canada
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $7 - Moomoo
FATE Stock Rises As Fate Therapeutics Showcases FT839 CAR T Data - StocksToTrade
MSN Money - MSN
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Fate hire gets 30,200 shares in Nasdaq-compliant award - Stock Titan
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
CAR-T Cell Therapy Market Will Generate Booming Growth Opportunities to 2030 | Novartis, Johnson & Johnson Services, Mustang, Sorrento Therapeutics, Fate Therapeutics etc. - industrytoday.co.uk
Single-dose FT819 data in 10 lupus patients heads to rheumatology meeting - Stock Titan
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting - ChartMill
Fate Therapeutics (NASDAQ: FATE) sets 2026 proxy votes and 7M-share plan boost - Stock Titan
Fate Therapeutics | DEF 14A: Definitive information statements - Moomoo
iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight - Barchart.com
Redmile (NASDAQ: FATE) corrects cash-settled swap reference price - Stock Titan
iPSC-Derived NK Cells Pipeline Set to Transform Cancer - openPR.com
Redmile (NASDAQ: FATE) shifts stake to SPV in internal reorg - Stock Titan
FATE Financials: Income Statement, Balance Sheet & Cash Flow | Fate Therapeutic - Stock Titan
Fate Therapeutics (FATE) Stock: Why Market Expansion (Breakdown Watch) 2026-04-20Social Buzz - UBND thành phố Hải Phòng
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases - marketscreener.com
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at t - Sahm
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Announces Data Presentation Of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate For The Broad Treatment Of Hematological Malignancies And Autoimmune Diseases Without The Need For Conditioning Chemotherapy - marketscreener.com
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference - MarketBeat
NK Cell Therapy Market Is Booming Rapidly with Strong Demand - openPR.com
Aug Wrap: Is Fate Therapeutics Inc part of any ETFDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenueTrend Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Fate Therapeutics Inc stock (US3025491025): Is its iPSC platform strong enough to unlock biotech ups - AD HOC NEWS
Fate Therapeutics Inc stock: Q2 2026 conferences signal active engagement - AD HOC NEWS
FATE Q4 2025 Earnings: Fate Therapeutics Inc. posts narrow EPS beat, no revenue reportedElite Trading Signals - UBND thành phố Hải Phòng
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences - GlobeNewswire
Fate Therapeutics plans appearances at 5 investor conferences by June - Stock Titan
Fate Therapeutics reports new employee inducement award under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Fate Therapeutics Announces New Employee Inducement Award - National Today
Fate Therapeutics Inc (F6T.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Street Watch: Is Fate Therapeutics Inc subject to activist investor interest2026 Rallies & Weekly Breakout Watchlists - baoquankhu1.vn
FATE Should I Buy - Intellectia AI
Fate Therapeutics Inc Stock: Pioneering iPSC Cell Therapies Amid Biotech Volatility - AD HOC NEWS
Fate Therapeutics (NASDAQ:FATE) Share Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
Scalable Biotech Manufacturing Unlocks a $14B Market - Sahm
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):